VIDEO: ANX007 shows visual function benefits in phase 2 study

ByRoger A. Goldberg, MD, MBA

ByEamon N. Dreisbach

Fact checked byChristine Klimanskis, ELS

In this Healio Video Perspective, Roger A. Goldberg, MD, MBA, overviews the results of the phase 2 ARCHER study investigating intravitreal ANX007 for the treatment of geographic atrophy, presented at the Retina Society meeting.

According to Goldberg, the primary endpoint of the study was the change in geographic atrophy lesion area, and prespecified functional endpoints included changes in best corrected visual acuity, low luminance visual acuity and low luminance visual deficit.

“ANX007, the ARCHER phase 2 study, showed consistent demonstration of visual function benefits across a whole variety of different baseline groups and characteristics and in the overall population itself despite not showing a change in the lesion area of growth through 12 months,” he said.

ANX007 was well tolerated, Goldberg said.

Published by:

Sources/Disclosures

Collapse

Source:

Goldberg R. Treatment of geographic atrophy secondary to age-related macular degeneration with intravitreal ANX007: Results of the ARCHER study. Presented at: Retina Society meeting; Oct. 11-14, 2023; New York.

Disclosures: Goldberg reports being an investigator and adviser for Annexon.